Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma

NCT00352859 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00352859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00352859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2006
Completion date
November 30, 2006
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell